Patients with MGUS and SMM require indefinite follow-up given their lifelong risk of progression to MM or related malignancy [32].
Such interventions may prevent progression and lifelong consequences, including the development of comorbidities.
Imagine a future where individuals can illustrate their progression of lifelong learning and training and its links to their real-world performance.
These complications have been associated with a 2.0 4.0 fold increase in premature cardiac disease and death versus non-diabetics. 1 Intensive treatment to improve glycemic control has been shown to prevent or delay disease onset and help mitigate progression of these lifelong complications.
Additionally, high recurrence rate and cancer progression impose the requirement for lifelong monitoring of patients after treatment.
This study was designed to evaluate the association of lifelong coping strategies and social support with progression of chronic stable angina (CSA) to acute coronary syndrome (ACS).
The variability of individual progressions between complete resilience and lifelong trauma-related disorders must be estimated as well, since they directly determine the long-term follow-up costs.
Because the microbiome is dynamically regulated by both genes and environment and, in turn, critically influences both physiology and lifelong health, its role in the development and progression of both T1D and T2D is being investigated.
Although the therapeutic efficacy is well recognised, a high recurrence rate of 60 70% and a progression rate of 15% dictate the need for lifelong follow-up and treatment.
